Amarantus BioSciences, Inc.
675 Almanor Avenue
Sunnyvale
California
94085
United States
Tel: 408-737-2734
Fax: 408-852-4427
Website: http://www.amarantus.com/
Email: info@amarantus.com
233 articles about Amarantus BioSciences, Inc.
-
Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities
4/27/2022
Amarantus Bioscience Holdings, Inc. today released a letter to its shareholders announcing it has entered into a non-binding term sheet to sell the Company's Engineered Skin Substitute (ESS).
-
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
1/2/2020
Amarantus Bioscience Holdings, Inc. announced that it has completed an exclusive worldwide sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products, a diversified cannabidiol -focused health sciences company.
-
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
11/21/2019
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa
-
Amarantus Provides Recapitalization Update to Shareholders
11/18/2019
Amarantus Bioscience Holdings, Inc. released a letter to its shareholders following the announcement of the binding term sheet to license the Company’s therapeutics subsidiaries’ technologies to Emerald Organic Products, an emerging CBD-focused health sciences company, and other recent events
-
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
11/14/2019
Topline results expected before the end of Q1/2020
-
Amarantus Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
10/24/2019
Amarantus Bioscience Holdings, Inc. announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc., a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels.
-
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
6/25/2019
Amarantus Bioscience Holdings, Inc. announced that it has entered into a Letter of Intent with The Alchemist’s Kitchen, a plant-based wellness company marketing the Plant Alchemy brand of health and wellness products, to establish a joint venture for commercialization of hemp based herbal smokable products ‘Herbal Smokes’ in addition to conducting research for cannabinoid derived addiction treatment, including smoking cessation, and other indications such as insomnia.
-
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
6/18/2019
Amarantus Bioscience Holdings, Inc. announced that positive results from in vitro and animal studies on MANF in the treatment of Wolfram Syndrome were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
-
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF
6/13/2019
Amarantus Bioscience Holdings, Inc. announced that subsidiary MANF Therapeutics was issued U.S. Patent No. 10,195,251 entitled ‘Methods of Treatment for Retinal Diseases Using MANF and CDNF’ that covers the use of mesencephalic astrocyte-derived neurotrophic factor or cerebral dopamine neurotrophic factor as a treatment for various ophthalmic disorders, including inherited retinal disorders, age-related macular degeneration and glaucoma.
-
Amarantus Releases Letter to Shareholders
5/31/2019
Amarantus Bioscience Holdings, Inc. released a letter to shareholders from President & CEO Gerald E. Commission
-
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
1/11/2019
Amarantus Bioscience Holdings, Inc. and IDEA Pharma Ltd have announced a highly original partnership, to bring together Amarantus' innovative therapeutics and diagnostics portfolio with IDEA's industry-leading path-to-market expertise.
-
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
12/3/2018
Todos Medical Ltd. announced that it has entered into a Joint Venture Agreement (JV Agreement) with biotechnology holding company Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) to develop LymPro Test® as a diagnostic blood test for Alzheimer’s disease.
-
Amarantus Provides Update on Elto Pharma Capital Formation Plan
6/7/2018
Amarantus Bioscience Holdings, Inc. provided an update to the marketplace on its capital formation plans for its wholly-owned subsidiary Elto Pharma, Inc.
-
Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding
2/27/2018
Amarantus BioScience Holdings, Inc. (OTCPK: AMBS) (the “Company” or AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries...
-
Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson's Disease
1/30/2018
The published data show that 1 week after MANF treatment, there is an increased release of dopamine, as well as increased dopamine turnover.
-
Amarantus Subsidiary Cutanogen Corporation Announces Issuance of U.S. Patent 14/299
1/23/2018
Once approved, ESS is eligible for 12 years of market exclusivity under the BPCIA.
-
Amarantus Subsidiary Cutanogen Corporation Announces Issuance of U.S. Patent 14/299
1/23/2018
Once approved, ESS is eligible for 12 years of market exclusivity under the BPCIA.
-
Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma
12/27/2017
The patents extend exclusivity for the use of MANF and CDNF in the treatment of retinal disorders in Europe into 2031.
-
Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease
12/20/2017
The issued patent extends coverage for MANF Therapeutics' use of MANF in the treatment of Parkinson's in Japan into 2031.
-
Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson's LID
12/8/2017
Both patents are titled "Treatment of Motor Symptoms and Movement Disorder Side Effects Associated with Parkinson’s disease treatments," and are valid into 2033.